Trenutni presek procesa vakcinacije protiv korona virusa u Srbiji
Sažetak
Prošlo je više od godinu dana od početka pandemije izazvane korona virusom (SARS-CoV-2). Timovi istraživača sarađuju na razvoju i unapređivanju vakcina protiv SARS-CoV-2. Četiri COVID-19 vakcine različitih tipova i proizvođača dostupne su u Srbiji od decembra 2020. godine, a građani mogu da se odluče za jednu od njih. Cilj ovog istraživanja bio je da napravi presek trenutne situacije procesa vakcinacije građana Srbije u pogledu istraživanja stavova i neželjenih efekata nakon primljene dve doze vakcine protiv virusa SARS-CoV-2. Nakon primene vakcine, očekivani su blagi do umereni neželjeni efekti, lokalni i sistemski.
Prikupljanje podataka izvršeno je putem online ankete pozivanjem građana da dobrovoljno pristupe popunjavanju upitnika u definisanom periodu od početka marta do 12. aprila 2021. godine.
Istraživanje je obuhvatilo 573 ispitanika prosečne starosti 43,55 ± 13,17 godina: 174 (30,37%) muškaraca i 399 (69,63%) žena,. Najveći broj ispitanika vakcinisano je Pfizer/BioNTech (40,14%) ili Sinopharm (42,93%) vakcinom, što je u skladu sa dostupnošću vakcina u Srbiji tokom perioda ispitivanja. Zastupljenost vakcine Pfizer/BioNTech bila je veća među ispitanicima muškog pola, zdravstvenim radnicima i populacijom mlađom od 30 godina. Najčešći prijavljeni lokalni neželjeni efekati bili su bol i osetljivost na mestu uboda. Od sistemskih neželjenih efekata najučestaliji su bili povišena temperatura, bol u mišićima/zglobovima i umor. Intenzitet neželjenih efekata bio je veći nakon druge doze, a njihovo trajanje je kod većine ispitanika iznosilo jedan dan.
Proces vakcinacije u Srbiji intenzivno traje. Masovna vakcinacija jeste put ka kontroli pandemije, kolektivnom imunitetu i smanjenju smrtnosti izazvane virusom SARS CoV 2.
Reference
Banerji A, Wickner PG, Saff R, Stone CA, Robinson LB, Long AA, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract 2021;9:1423-37. [CrossRef] [PubMed]
Baraniuk C. Covid-19: What do we know about Sputnik V and other Russian vaccines? BMJ 2021; 372:743. [CrossRef] [PubMed]
Centers for Disease Control and Prevention COVID-19 Response Team. Allergic reactions including anaphyl-axis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. MMWR 2021;70(2):46-51. [CrossRef] [PubMed]
Earnshaw VA, Eaton LA, Kalichman SC, Brousseau NM, Hill EC, Fox AB. COVID-19 conspiracy beliefs, health behaviors, and policy support. Translational Behavioral Medicine 2020;10(4):850-6. [CrossRef] [PubMed]
Hajissa K, Mussa A. Positive aspects of the mRNA platform for SARS-CoV-2 vaccines. Hum Vaccin Immunother 2021;8:1-3. [CrossRef] [PubMed]
Knoll MD, Wonodi C. Oxford–AstraZeneca COVID-19 vaccine efficacy. Lancet 2021;397(10269):72-4. [CrossRef] [PubMed]
Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020; 586 (7830):589-93. [CrossRef] [PubMed]
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383(27):2603-15. [CrossRef] [PubMed]
Pu J, Yu Q, Yin Z, Zhang Y, Li X, Li D, et al. An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine. MedRxiv 2020; [CrossRef]
Ritchie H, Ortiz-Ospina E, Beltekian D, Mathieu E, Hasell J, Macdonald B, et al. Serbia: Coronavirus pandemic country profile. “Cited 2021 April 12”; Available from: URL: https://ourworldindata.org/coronavirus/country/serbia
Sallam M, Dababseh D, Eid H, Al-Mahzoum K, Al-Haidar A, Taim D, et al. High rates of covid-19 vaccine hesitancy and its association with conspiracy beliefs: A study in Jordan and Kuwait among other Arab countries. Vaccines 2021;9(1):42-58. [CrossRef] [PubMed]
Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in older people. Age Ageing 2021;50(2):279-83. [CrossRef] [PubMed]
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised con-trolled trials in Brazil, South Africa, and the UK. Lancet 2021;397(10269):99-111. [CrossRef] [PubMed]
Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med 2020;383(25):2439-50. [CrossRef] [PubMed]
Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020;395(10223):470–3. [CrossRef] [PubMed]
Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet 2020; 395(10229): 1014-5. [CrossRef] [PubMed]
Wilson SL, Wiysonge C. Social media and vaccine hesitancy. BMJ Glob Health 2020;5(19):e004206. [CrossRef] [PubMed]
Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials. JAMA 2020; 324(10):951-60. [CrossRef] [PubMed]
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021;21(1):39-51. [CrossRef] [PubMed]
Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an in-activated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21(2):181-92. [CrossRef]
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020;396(10249):479-88. [CrossRef] [PubMed]